Abstract PPARγ-agonists enhance insulin sensitivity and improve glucose utilization in diabetic patients. Adverse effects of PPARγ-agonists include volume retention and edema formation. Recent observations pointed to the ability of PPARγ agonists to enhance transcription of the serum and glucocorticoid-inducible kinase SGK1, a kinase that is genomically upregulated by mineralocorticoids and stimulates various renal channels and transporters including the renal epithelial Na + channel ENaC. SGK1 has been proposed to mediate the volume retention after treatment with PPARγ agonists. To test this hypothesis, food containing the PPARγ agonist pioglitazone (0.02%, i.e., approximately 25 mg/kg bw/day) was administered to gene-targeted mice lacking SGK1 (sgk1
Introduction
Peroxisome proliferator-activated receptor gamma (PPARγ) is a ligand-dependent transcription factor that belongs to the nuclear receptor family [4] . PPARγ is highly expressed in white adipose tissue where it controls adipocyte differentiation and lipid storage [4] . Pharmacological activation of PPARγ by thiazolidinediones such as pioglitazone or rosiglitazone has been shown to enhance insulin sensitivity and to lower plasma glucose concentrations particularly in patients with insulin resistance [11, 32, 42] . Accordingly, PPARγ agonists are now well-established drugs widely used in the treatment of type 2 diabetes [37, 39] . PPARγ agonists have further been shown to decrease proteinuria [5] and counteract renal fibrosis [30, 50] .
The use of the PPARγ agonists has, however, been impeded by their volume retaining properties [18, 22, 49] . In patients with congestive heart failure (CHF), treatment with PPARγ agonists was associated with decompensation and occurrence of pulmonary edema [35] . Thus, the use of PPARγ agonists is not recommended in patients with CHF [45] .
PPARγ is expressed in kidney and is particularly abundant in the inner medulla [20] . Therefore, the volume retaining effect of PPARγ-agonists may be due to stimulation of the epithelial sodium channel (ENaC) in the distal nephron [26] . Accordingly, gene-targeted mice with a collecting duct-specific deletion of PPARγ are apparently protected against PPARγ agonists-induced fluid retention [51] .
Two mechanisms have been invoked to mediate the stimulation of ENaC and the subsequent fluid retaining by PPARγ activation. On the one hand, PPARγ agonists were found to upregulate mRNA levels of SCNN1G encoding for the gamma subunit of ENaC in a mouse inner medullary collecting duct cell line [19] . On the other hand PPARγ agonists have been shown to stimulate the transcription of the serum and glucocorticoid-inducible kinase SGK1 [22] , which, in turn, was suggested to enhance the surface expression of ENaCα [22] . In three well-established cell culture models of the renal principal cell type, PPARγ agonists did not alter basal or insulin-stimulated ENaC activity and may thus be effective through additional mechanisms [36] , which, at least in theory, could be similarly sensitive to SGK1.
SGK1 has originally been identified as a gene under transcriptional control of glucocorticoids [15] but later found to be genomically stimulated by mineralocorticoids [10, 31, 34] . SGK1 is expressed in the aldosterone-sensitive distal nephron [31] , where it stimulates the epithelial Na + channel ENaC [1, 10, 13, 29, 34] . Beyond that, SGK1 has been shown to stimulate a wide variety of further renal and extrarenal ion channels and transporters [28] . Gene-targeted mice lacking SGK1 (sgk1 −/− ) excrete similar amounts of salt under regular salt intake but cannot adequately decrease renal NaCl elimination after exposure to salt-depleted diet. As a result, salt deplete diet leads to marked decrease of glomerular filtration rate and blood pressure in sgk1
mice [46] . The present study aimed to define the in vivo role of SGK1 in the volume retaining effects of PPARγ agonists. To this end, sgk −/− mice and their wild-type littermates (sgk1 +/+ ) were treated with the PPARγ agonist pioglitazone.
Materials and methods

Animal experimentation
All animal experiments were conducted according to the guidelines of the American Physiological Society and the German law for the welfare of animals and were approved by local authorities.
Mice deficient in SGK1 (sgk1
) and their wild-type littermates (sgk1 +/+ ) were generated and bred as previously described [24, 46] . They were fed a control diet (C1000, Altromin, Lage, Germany) and had free access to tap water. After a control period, the food pellets were replaced by custom-made pellets containing 0.2 g/kg pioglitazone with otherwise identical composition (C1000 + Pioglitazone, Altromin, Lage, Germany). The drug intake approached 20-30 mg/kg bw/day, a dosage previously shown to be effective [47] .
For the evaluation of renal Na + excretion, body weight and fluid and food intake, sgk1 −/− and sgk1 +/+ mice were placed individually in metabolic cages (Techniplast Hohenpeissenberg, Germany) for 24-h urine collection with free access to tap water and the respective diet [40] . Mice were studied before treatment, during the first 8 days and after 4 weeks of pioglitazone treatment. The inner wall of the metabolic cages was siliconized and urine was collected under water-saturated oil. For comparison, sgk1 −/− and sgk1 +/+ mice were fed the control diet C1000 and followed over 4 weeks.
To study the role of ENaC inhibition in pioglitazoneinduced volume retention, sgk1 −/− and sgk1 +/+ mice were treated for 8 days with the ENaC blocker triamterene (Sigma, Taufkirchen, Germany) in the drinking water (200 mg/l, pH 4, light-protected) and the pioglitazonecontaining diet. The triamterene intake approached 35-40 mg/kg bw/day, a dosage previously shown to be effective [21] .
To obtain blood specimens, animals were lightly anesthetized with diethylether (Roth, Karlsruhe, Germany), and about 150 μl of blood was withdrawn into heparinized hematocrit capillaries by puncturing the retro-orbital plexus. Hematocrit was determined by centrifugation. Blood loss was replaced with 200 μl 0.9% NaCl subcutaneously, and the animals were allowed to recover for 2 weeks.
Expression of SGK1 was determined early (3-4 days) after treatment to elucidate, whether alterations in SGK1 transcript levels or protein expression precede volume expansion. Body weight was determined daily from the beginning, and plasma hormone levels, plasma volume, and blood pressure, 2-4 weeks after the beginning of the treatment to disclose the effect of chronic PPARγ activation on the respective functional parameters.
Determination of plasma volume
Plasma volume was assessed by dye dilution using Evans Blue (Sigma, Taufkirchen, Germany). Mice were anesthetized with diethylether and 30-50 μl of an Evans Blue stock solution (3 mg/ml in 0.9% NaCl) was injected intravenously into the left retro-orbital plexus using a 30-gauge insulin syringe (BD micro-fine, Heidelberg, Germany). The exact applied volume was determined by weighing the syringe before and after injection. Repeated blood samples (20-25 μl) were drawn fom the right retroorbital plexus during superficial diethylether anesthesia after 30, 60, and 100 min, which yielded a volume of 10 μl plasma after centrifugation. Absorbance was measured at 620 nm against blank mouse serum after recovery in 90 μl phosphate-buffered saline (PBS tablets, Invitrogen, Karslruhe, Germany). Plasma concentrations of Evans Blue were calculated using the stock solution dissolved in mouse serum as a standard. To correct for the clearance of Evans Blue during distribution time, linear regression of the log transformed concentrations was applied to calculate the y-intercept which represents the imaginary concentration of Evans Blue in its final distribution volume [16] . r 2 approached 0.94±0.07 (SD). Division of the applied dose of Evans Blue (in mg) by the y-intercept (in mg/ml) resulted in the distribution volume of Evans Blue which was normalized for body weight.
Measurement of Na + , creatinine, aldosterone, and leptin concentrations Plasma and urinary concentrations of Na + were measured by flame photometry (AFM 5051, Eppendorf, Germany) and plasma aldosterone concentrations using a commercial RIA kit (Demeditec, Kiel, Germany). Plasma and urinary creatinine concentrations were measured using an enzymatic colorimetric method (creatinine PAP, Lehmann, Berlin, Germany). Plasma leptin levels were determined using an ELISA kit (Linco, St. Charles, USA).
Determination of systolic blood pressure Systolic arterial blood pressure was determined by the tailcuff method (IITC, Model 179, CA, USA) under control diet and 3 weeks after treatment with pioglitazone. As reviewed recently [33] , the tail-cuff approach to determine arterial blood pressure requires certain precautions to reduce the stress of the animals, including appropriate training of the mice over multiple days and adequate prewarming to dilate the tail artery. The animals were placed in a heated chamber at an ambient temperature of 30°C for 15 min. For each animal, 10-20 blood pressure traces were recorded in one session. The readings from 3 days were then averaged to obtain a mean blood pressure under the respective treatment. All recordings and data analysis were done using a computerized data acquisition system and software (PowerLab 400 and Chart 4, both AdInstruments, CO, USA). All measurements were done by one person (FA) during a defined time (between 2 and 4 P.M.).
Determination of plasma concentrations of pioglitazone
Quantitative determination of pioglitazone in plasma was performed using an high performance liquid chromatography (HPLC) tandem mass spectrometry (MS/MS) assay after protein precipitation with methanol. A homolog was used as internal standard (IS). Plasma samples were cleared from any precipitates by centrifugation at 13,700×g for 5 min. After adding 15 μl of the working solution containing IS (0.5 μg/ml in acetonitrile/water 60/40 v/v) to 5 μl of the plasma samples, proteins were precipitated by addition of 150 μl methanol. After centrifugation at 3,000×g for 5 min, 30 μl of the supernatant was recovered and diluted by adding 750 μl acetonitrile/water (60/40 v/v). An aliquot of 10 μl was injected. The HPLC system consisted of an HTC PAL autosampler (CTC Analytics, Zwingen, Switzerland) and an Agilent 1100 HPLC equipment (Agilent Technologies, Böblingen, Germany). Chromatography was performed on a Chromolith SpeedROD® RP-18e, ID 3 mm using gradient elution. The mobile phase consisted of two components: solvent A (0.1% formic acid) and solvent B (acetonitrile). At a flow rate of 0.8 ml/min, an isocratic period of 0.6 min at 100% A was followed by a linear gradient (0 to 90% B/0.6 to 1.5 min) and a period from 1.5 to 3.0 min at 90% B. Equilibration was achieved by flushing the column with 100% acetonitrile over 30 s at a flow rate of 2.0 ml/min. Detection was performed using an Applied Biosystems (Forster City, CA, USA) 4000 Qtrap triple quadrupole mass spectrometer operated in the positive turbo-ion-spray mode by applying multiple reaction monitoring (MRM). The used mass transition for pioglitazone was 357.1 to 134.1 amu.
In situ hybridization
In situ hybridization experiments were performed to investigate whether pioglitazone increases SGK1 transcript levels in the kidney. Expression was studied in sgk1 +/+ mice after a 3-day treatment with pioglitazone-containing diet corresponding to the highest slope of body weight gain. Control mice were treated over 3 days with control diet (n= 3 each). Kidneys were harvested after retrograde perfusion with phosphate-buffered 4% paraformaldehyde (pH 7.4) through cannulation of the infrarenal aorta. Anesthesia was achieved with tribromethanol (250 mg/kg bw i.p.) and ketamin (50 mg/kg bw i.m.).
Perfused kidneys were kept in paraformaldehyde overnight and then transferred to phosphate-buffered saline. After embedding in paraffin-dewaxed paraffin, 5 μm tissue sections were hybridized as described [25, 27] . The mixture contained 35 S-labeled RNA antisense murine SGK1 probe of 1,400 bp length (500 ng/ml) in 10 mM Tris-HCl, pH 7.4/50% (v/v) deionized formamide/600 mM NaCl/ 1 mM EDTA/0.02% polyvinylpyrrolidon/0.02% Ficoll/ 0.05% bovine serum albumin/10% dextrane sulfate/ 10 mM dithiothreitol/denatured sonicated salmon sperm DNA 200 μg/ml/rabbit liver tRNA 100 μg/ml. Hybridization with RNA probes proceeded at 42°C for 18 h. Slides were then washed and incubated for 1 h at 55°C in 2× standard saline citrate. Nonhybridized single-stranded RNA probes were digested by RNase A (20 μg/ml) in 10 mM Tris-HCl, pH 8.0/0.5 M NaCl for 30 min at 37°C. Tissue slide preparations were autoradiographed for 3 weeks and stained with hematoxylin/eosin. Control hybridizations were performed with the corresponding α-35 S-labeled murine SGK1 sense RNA probe. Sufficiently strong staining required exposure periods of >14 days, which resulted in considerable background activity, as apparent from seemingly luminal staining.
Quantitative real-time PCR
To quantify SGK1 transcript levels in the kidney, treated and untreated sgk1 +/+ mice were killed after 3 days of pioglitazone or control treatment (n=10-11 each), and the kidneys were rapidly frozen on liquid nitrogen. PPARγ transcript levels were quantified in untreated sgk1 −/− and sgk1 +/+ mice (n = 7 each). Automated disruption and homogenization of frozen tissue of whole kidneys was performed using the MagNa Lyser Instrument™ (Roche Diagnostics, Mannheim, Germany). Cleared cell lysate was transferred for further RNA purification (RNAeasy Mini Kit, Qiagen, Hilden, Germany). Subsequently 1 μg of total RNA was reverse transcribed to cDNA utilizing the reverse transcription system (Bioscience, USA) with oligo(dT) primers according to the manufacturer's protocol. To determine SGK1 and PPARγ transcript levels, quantitative real-time PCR with the LightCycler System® (Roche Diagnostics, Mannheim, Germany) was applied using the primers 5′ TGTCTTGGGGCTGTCCTGTATG 3′ (forward) and 5′ GCTTCTGCT GCTTCCTTCACAC 3′ (reverse) for mSGK1, and 5′ CTGTTATGGGTGAAACTCTGGGAG 3′ (forward) and 5′ ATAGGCAGTGCATCAGCGAA 3′ (reverse) for mPPARγ [48] yielding products with 406 bp (mSGK1) and 72 bp length (mPPARγ). PCR reactions were performed in a final volume of 20 μl containing 2 μl cDNA, 2.4 μl MgCl 2 (3 μM), 1 μl primermix (0.5 μM of both primers), 2 μl cDNA Master SybrGreen I mix (Roche Molecular Biochemicals, Mannheim, Germany), and 12.6 μl DEPC-treated water. The transcript levels of the housekeeping gene GAPDH were determined for each sample using a commercial primer kit (Search LC, Heidelberg, Germany). PCR reactions for GAPDH were performed in a final volume of 20 μl containing 2 μl cDNA, 2 μl primer mix (Search LC, Heidelberg, Germany), 2 μl cDNA Master Sybr Green I mix (Roche Molecular Biochemicals, Mannheim, Germany) and 14 μl DEPCtreated water. The target DNA was amplified during 35 cycles of 95°C for 10 s, 68°C for 10 s, and 72°C for 16 s, each with a temperature transition rate of 20°C/s, a secondary target temperature of 58°C, and a step size of 0.5°C. Melting curve analysis was performed at 95°C, 0 s; 58°C, 10 s; 95°C, 0 s to determine melting temperatures of primer dimers and the specific PCR products. Melting curve analysis confirmed the amplified products. Finally, results were calculated as a ratio of the target vs house keeping gene GAPDH transcripts.
Immunofluorescence
For the analysis of SGK1 protein expression in the kidney, sgk1 +/+ and sgk1 −/− mice were killed after 3 days of pioglitazone or control treatment (n=3 each) and the kidneys were rapidly frozen on liquid nitrogen. For comparison, mice treated with a low-salt diet (C1036, Altromin, Lage, Germany) for 4 days were killed (n=2 each). Frozen sections (3 μm) were fixed in acetone Similar values were obtained after a 4-week treatment (11.3±1.5 μM in sgk1 +/+ mice and 10.1±0.9 μM in sgk1 −/− mice, n=6 each).
To determine, whether pioglitazone influences the transcript levels of SGK1, renal tissue was analyzed in sgk1 +/+ mice by in situ hybridization and quantitative RT-PCR after a 3-day treatment with pioglitazone. As shown in Fig. 1a , pioglitazone treatment increased SGK1 mRNA abundance in the collecting duct of the renal medulla. In the sections of renal cortex, SGK1 expression tended to be stronger in the distal tubules and connecting ducts of treated mice, whereas no difference was visible between treated and untreated animals in glomeruli and proximal tubules. According to quantitative RT-PCR, pioglitazone treatment significantly increased SGK1 transcript levels in whole kidneys (1,989±528 copies in untreated, 4,474± 1047 copies in treated mice) without significantly affecting GAPDH mRNA levels (218,828±51,606 copies in untreated, 280,563±55,101 copies in treated mice, Fig. 1b) . Expressed as a ratio of SGK1 over GAPDH, SGK1 transcript levels were induced by a factor of 1.7 (Fig. 1c) . The increase in SGK1 transcript levels was paralleled by an increased SGK1 protein expression as evidenced by enhanced immunofluorescence in kidney sections from pioglitazone-treated sgk1 +/+ mice (Fig. 2) . Staining was −/− mice treated with control diet, pioglitazone-containing diet for 3 days or low salt diet for 4 days (tenfold magnification). Nuclei are stained blue with DAPI confined to the distal nephron as confirmed by colocalization with 11β-hydroxysteroid dehydrogenase type 2. The intensity of the staining after pioglitazone treatment was similar to that obtained in kidneys from mice treated with a low-salt-diet, a maneuver-stimulating aldosterone secretion and SGK1 protein expression. In kidneys from sgk1 −/− mice, no specific staining was obtained.
If pioglitazone treatment was followed by extracellular volume expansion, then the treatment should increase body weight. As illustrated in Fig. 3 , body weight indeed increased during the treatment in both, sgk1 +/+ and sgk1 −/− mice. However, the increase of body weight was significantly more pronounced in sgk1 +/+ mice than in sgk1 −/− mice both after 8-day (+1.5±0.2 g, vs +1.0±0.2 g, n=12 each) and 4-week (+2.2±0.3 g, vs +1.3±0.2 g, n=12 each; Fig. 3a) treatment. During control experiments, no appreciable net body weight gain was observed after 8 days or 4 weeks ( Fig. 3a and b) . After simultaneous treatment with the ENaC blocker triamterene and pioglitazone, body weight was decreased in both genotypes to a similar extent during the first 3 days (Fig. 3a) . After that, sgk1 −/− mice continued to lose weight, whereas sgk1 +/+ mice restored their body weight and returned to their baseline weight.
Extracellular volume expansion should further increase plasma volume and, thus, decrease hematocrit. Pioglitazone treatment indeed decreased the hematocrit significantly in both, sgk1 +/+ and sgk1 −/− mice ( Table 1) . The effect was, however, again significantly more pronounced in sgk1 +/+ mice (−6.5±1.0%, n=12) than in sgk1 −/− mice (−3.1± 0.6%, n = 12) after 4 weeks of treatment. Plasma Na + concentration increased significantly in sgk1 +/+ mice and tended to increase in sgk1 −/− mice (Table 1) .
To assess plasma volume directly, a dye dilution method using Evans Blue was applied. The dye tightly binds to plasma proteins (mainly albumin) and is thus a reliable indicator for plasma volume. As illustrated in Fig. 4 , pioglitazone treatment increased significantly the ratio of plasma volume/body weight in sgk1 +/+ mice, but not in sgk1
mice. Extracellular volume expansion should decrease aldosterone release. As reported earlier [46] , plasma aldosterone concentration was higher in sgk1 −/− than in sgk1 +/+ mice before pioglitazone administration (Fig. 5) . Pioglitazone treatment significantly decreased plasma aldosterone values in both genotypes. However, plasma aldosterone levels remained significantly higher in sgk1 −/− mice after treatment. The decrease of plasma aldosterone concentration tended to be larger in sgk1 +/+ mice than in sgk1 −/− mice, a difference, however, not reaching statistical significance. Even though pioglitazone treatment induced extracellular volume expansion, it significantly decreased blood pressure from 112±4 to 95±4 mmHg in sgk1 +/+ mice (by −14. sgk1 +/+ mice, a difference, however, not reaching statistical significance (Fig. 6) .
As leptin is released from adipocytes, plasma leptin concentrations increase with adipocyte mass. Pioglitazone treatment increased plasma leptin concentrations in both genotypes to a similar extent (Fig. 7) .
Discussion
The present observations disclose an influence of the serum and glucocorticoid inducible kinase SGK1 on the volumeretaining effect of pioglitazone. Pioglitazone treatment increased renal SGK1 mRNA and protein expression, which is apparently required for the full effect of the PPARγ agonist on extracellular fluid volume.
Differences in the observed effects between sgk1 +/+ and sgk1 −/− mice were not attributable to differences in PPARγ expression or pioglitazone plasma levels. The latter were in the lower micromolar range (10-15 μM), which is comparable to levels measured in volunteers after oral ingestion of 30 mg pioglitazone (3 μM; [44] ). At those concentrations, pioglitazone does increase extracellular fluid volume, as previously shown for PPARγ agonists [18, 22, 49] . According to the present study, SGK1 may contribute to, but does not fully account for, the fluid retaining effects of pioglitazone. Volume retention was estimated from body −/− mice point to SGK1-independent effects of pioglitazone on sodium and fluid reabsorption. ENaC activity and expression was found to be directly stimulated by pioglitazone in a mouse collecting duct cell line [19] , but not in other studies using CCD principal cell lines [36] . Treatment with triamterene prevented the body weight gain in sgk1 +/+ mice, an observation indeed pointing to the involvement of ENaC in pioglitazone-induced volume retention. ENaC is regulated by SGK1, which stimulates ENaC expression and activity [1, 10, 13, 29, 34] . Interestingly, sgk1
−/− mice under combined treatment were more susceptible to the diuretic action of triamterene and continued to lose weight over the treatment period. The sensitivity of sgk1 −/− mice to triamterene mice clearly points to SGK1 independent ENaC activity. Beyond that, the possibility must be considered that the volume retaining activity of SGK1 is not exclusively due to stimulation of ENaC. As a matter of fact, in vitro experiments disclosed the ability of SGK1 to stimulate a wide variety of carriers and channels [28] including the renal tubular Na
The actions of the PPARγ agonist pioglitazone on the distal nephron strongly resemble the actions of aldosterone, which also exerts both, SGK1-independent direct [3] and SGK1-dependent indirect effects on ENaC expression and activity [1, 10, 13, 29, 34] . As part of a counter-regulation to the pioglitazone-induced volume retention, endogenous aldosterone levels were suppressed. However, plasma aldosterone levels remained significantly higher in sgk1 −/− mice under pioglitazone treatment.
The administration of pioglitazone sensitizes tissues for the action of insulin [11, 32, 42] . The effects of aldosterone and insulin or IGF-1 may be additive [17] . Insulin stimulates SGK1 and is thus expected to enhance ENaC activity and renal Na + reabsorption [6] [7] [8] . SGK1 contributes to the regulation of renal Na + excretion by aldosterone, insulin, and IGF-1. As the effect of aldosterone is only partially dependent on the presence of SGK1, the effects of aldosterone and SGK1 may be additive. However, ADH or insulin do not further stimulate ENaC in cells expressing constitutively active SGK1 [2] .
Along those lines, acute intravenous application of insulin (under euglycemic conditions) significantly decreased fractional urinary Na + excretion without affecting blood pressure and GFR in sgk1 +/+ mice, an effect significantly blunted in sgk1 −/− mice [23] . Those experiments demonstrate a critical role of SGK1 in insulininduced renal Na + retention. In contrast, PPARγ agonists showed no effect on basal or insulin-stimulated ENaC activity [36] .
The salt retaining effects of PPARγ agonists were expected to increase blood pressure. The opposite is observed, i.e., decrease of blood pressure. A hypotensive effect of PPARγ agonists is similarly observed in clinical studies and may be due to a vasodilating effect of PPARγ agonists [38] . Even though the blood pressure lowering effect is apparent in both, sgk1 −/− and sgk1 +/+ mice, it is more pronounced in sgk1 −/− mice. Thus, SGK1 counteracts the blood pressure-lowering effect of pioglitazone. The salt-retaining effect of SGK1 is expected to impact on blood pressure control. As a matter of fact, SGK1 expression is deranged in the salt sensitive Dahl rat [14] . Moreover, moderately enhanced blood pressure values are observed in individuals carrying a variant of the SGK1 gene, affecting some 3-5% of unselected Caucasians [9, 43] . Interestingly, the gene variant is associated with enhanced insulin sensitivity of blood pressure [43] .
SGK1 does not only participate in electrolyte balance by its influence on renal elimination, but mediates at least, in part, the effect of mineralocorticoids on salt appetite [41] . Thus, SGK1 plays a dual role in mineralocorticoidregulated NaCl homeostasis. Whether enhanced salt appetite contributes to extracellular volume expansion under PPARγ treatment, cannot be decided on the basis of our observations. Pioglitazone leads to enhanced food and, thus, salt intake, an effect presumably accounting for the enhanced urinary Na + elimination during pioglitazone treatment.
Leptin levels were elevated during pioglitazone treatment, to a similar extent, in both genotypes. The increase of leptin levels may point to an increase in white adipocyte mass, as leptin levels positively correlate with white fat mass [12] . This also implies that the observed body weight gain does not fully represent volume retention but also reflects an increase in white adipocyte mass. The SGK1-independent effect of PPARγ agonists on white fat mass may have contributed to the gain of body weight.
In conclusion, PPARγ agonists upregulate expression of SGK1, which contributes to but does not fully account for extracellular volume expansion after treatment with these drugs. with Volker Vallon. 
